We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Uric Acid Levels Predict Death in Acute Coronary Syndrome

By HospiMedica International staff writers
Posted on 02 May 2012
Elevated levels of uric acid are predictive of one-year mortality in patients with acute coronary syndrome (ACS), according to a new study.

Researchers at the German Heart Center (Deutsches Herzzentrum; Munich, Germany) conducted a study involving 5,124 patients with ACS who underwent percutaneous coronary intervention (PCI) to evaluate whether uric acid levels have any prognostic value. More...
The participants were classified into four uric acid quartiles: quartile 1 (1.3 to <5.3 mg/dL), quartile 2 (5.3 to <6.3 mg/dL), quartile 3 (6.3 to <7.5 mg/dL), and quartile 4 (7.5 to 18.4 mg/dL). Of the participants, 1,629 had acute ST-segment elevation myocardial infarction (STEMI), 1,332 had acute non-STEMI, and 2,163 had unstable angina. The primary end point was one-year mortality.

The results showed that during follow-up, there were 450 deaths: 80 deaths in quartile 1, 77 in quartile 2, 72 in quartile 3, and 221 in quartile 4. The researchers found that uric acid measurement improved the discriminatory power of the predictive model regarding one-year mortality. After adjustment for traditional cardiovascular (CV) risk factors, renal function, and inflammatory status, the association between uric acid and mortality remained significant, with a 12% increase in the adjusted risk for one-year mortality for every 1 mg/dL increase in the uric acid level. The study was published in the May 1, 2012, issue of the American Journal of Cardiology.

“Elevated levels of uric acid are an independent predictor of one-year mortality across the whole spectrum of patients with acute coronary syndromes treated with percutaneous coronary intervention,” concluded lead author Gjin Ndrepepa, MD, and colleagues.

Related Links:

German Heart Center





Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Tourniquet System
heidi– mein Tourniquet
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Six-month FlexPulse IDE data show positive outcomes with Abbott’s TactiFlex Duo catheter, confirming safety and efficacy seen in the CE Mark study for complex AFib (photo courtesy of Abbott)

Dual-Energy Ablation and Conduction System Pacing Show Positive Early Outcomes

Atrial fibrillation and other arrhythmias are common in both hospitalized and ambulatory patients, often complicating hemodynamic stability, stroke prevention, and perioperative care. Within this context,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.